UKGrowth Network

UK company record

OMass Therapeutics

Drug discovery (native mass spectrometry / membrane protein platform)

CandidateCore UK
Open interactive recordCompanies House profile

Snapshot

UK location
Oxford · South East
Sector
Biotech & techbio
Latest recorded round
Series B
Latest recorded amount
£75.5M (extended with further £10M from British Patient Capital, 2023)
Date
2023-05-01

Legal-identity layer

Candidate identity.

Selected legal name
OMASS THERAPEUTICS LIMITED
Company number
10028228
Companies House status
active
Incorporated
2016-02-26

Investors

Current directors and active controllers

  • ASHTON, Christopher PhilipCurrent director
  • BERNSTEIN, DianaCurrent director
  • BILLER, Scott, Dr (Phd)Current director
  • CRESPO-MARTIN, Laia, PhdCurrent director
  • DEEGAN, Rosamond Margaret ChevallierCurrent director
  • FRANCHIMONT, Nathalie Marie Berthe MichelleCurrent director
  • HODGKIN, Edward EliotCurrent director
  • JOFFRIN, Pierre-Louis EmmanuelCurrent director
  • MONTAGU DAOUST, Jonathan DeaneCurrent director
  • Oxford Science Enterprises Holdings Ii LimitedActive controller
  • SCHAFER, Carol AnneCurrent director
  • Syncona LimitedActive controller
  • BRISTER, David Johndirector
  • GERAGHTY, James Arthurdirector
  • HOPPER, Jonathan, Doctordirector
  • HUMM, Roger Jamessecretary
  • HUMM, Roger Jamesdirector
  • JONIKAS, Magdalena Annadirector
  • MACKINNON, Lachlan Tomdirector
  • Oxford Science Enterprises Holdings Ii LimitedFormer controller
  • Oxford Sciences Innovation PlcFormer controller
  • RICHARDS, William Graham, Professordirector
  • ROBINSON, Carol, Professor Damedirector
  • VOLCK, Birgitte, Drdirector

Funding rows

Sources